politics
Eli Lilly's new weight-loss drug shows significant effectiveness in trials
21 Mayıs 2026The Guardian
- Eli Lilly has announced that its new weight-loss drug, retatrutide, has shown promising results in a large trial, leading to an average weight loss of 28% among participants. The drug, which is a once-weekly triple hormone receptor agonist, resulted in participants losing an average of 70.3 lbs over 80 weeks, with n…
- This performance surpasses that of existing obesity medications on the market.
- Obesity is a major public health concern globally, with existing treatments often falling short of expectations. Eli Lilly's retatrutide trial results come at a time when there is increasing demand for effective weight-loss solutions, particularly those that can deliver substantial results with manageable dosing sch…
- The significant weight loss achieved with retatrutide could represent a breakthrough in obesity treatment, especially considering the ongoing challenges many face with current options. The data suggests that this drug may not only be more effective but could also reshape the landscape of obesity management, potentia…
NewsAI özeti
This article is for informational purposes only and should not be considered medical advice. Consult a healthcare professional for personalized guidance.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.